Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...